Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’sdisease ARISE will evaluate the efficacy of solengepras as an adjunctive ...
Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson'sdisease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...